Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review


Cite item

Full Text

Abstract

Introduction::Armodafinil is a psychostimulant that promotes alertness, and it has been shown to improve attention, memory, and fatigue in healthy adults and adults with neurodevelopmental conditions that share symptoms with Attention Deficit Hyperactivity Disorder (ADHD). It is generally well tolerated and safe, and most of the adverse events reported are considered not serious. However, the available evidence on the efficacy of armodafinil for the treatment of ADHD in adults is scarce.

Objective::The present review aims to perform a systematized search of the available evidence on the possible therapeutic benefit of armodafinil treatment in adult patients with ADHD.

Methods::A literature review using PubMed was conducted to compile and summarize the available clinical and scientific evidence on the possible use of armodafinil as a pharmacological treatment in adult patients with ADHD.

Results::From the 86 articles reviewed, the available evidence showed that both acute and chronic treatment with armodafinil can improve wakefulness, memory, impulse control, and executive functions in adults with sleep disorders and other conditions. In addition, evidence of improvement in cognitive functions and mood alterations in other neuropsychiatric conditions was shown.

Conclusion::Armodafinil could be useful for the treatment of ADHD in adults, according to the review of the literature from both pre-clinical and clinical studies.

About the authors

Reyna Lamas-Aguilar

Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez

Email: info@benthamscience.net

Araceli Diaz-Ruiz

Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez

Email: info@benthamscience.net

Luz Navarro

Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México

Email: info@benthamscience.net

Raúl Miranda-Ojeda

The Mind Project, Office for Equity, Diversity, Inclusion, and Belonging,, Harvard University

Email: info@benthamscience.net

María de los Ángeles Martínez-Cárdenas

Departamento de Atención a la Salud, Universidad Autónoma Metropolitana Unidad Xochimilco

Email: info@benthamscience.net

Alfonso Mata-Bermudez

Departamento de Atención a la Salud,, Universidad Autónoma Metropolitana Unidad Xochimilco

Author for correspondence.
Email: info@benthamscience.net

Camilo Rios

Dirección de Investigación, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra

Author for correspondence.
Email: info@benthamscience.net

References

  1. Salvi, V.; Migliarese, G.; Venturi, V.; Rossi, F.; Torriero, S.; Viganò, V.; Cerveri, G.; Mencacci, C. ADHD in adults: Clinical subtypes and associated characteristics. Riv. Psichiatr., 2019, 54(2), 84-89. doi: 10.1708/3142.31249 PMID: 30985833
  2. Memarmoghaddam, M.; Torbati, H.T.; Sohrabi, M.; Mashhadi, A.; Kashi, A. Effects of a selected exercise programon executive function of children with attention deficit hyperactivity disorder. J. Med. Life, 2016, 9(4), 373-379. doi: 10.22336/jml.2016.0410 PMID: 27928441
  3. Spera, V.; Maiello, M.; Pallucchini, A.; Novi, M.; Elefante, C.; De Dominicis, F.; Palagini, L.; Biederman, J.; Perugi, G. Adult attention-deficit hyperactivity disorder and clinical correlates of delayed sleep phase disorder. Psychiatry Res., 2020, 291, 113162. doi: 10.1016/j.psychres.2020.113162 PMID: 32554185
  4. Wolraich, M.L.; Hagan, J.F., Jr; Allan, C.; Chan, E.; Davison, D.; Earls, M.; Evans, S.W.; Flinn, S.K.; Froehlich, T.; Frost, J.; Holbrook, J.R.; Lehmann, C.U.; Lessin, H.R.; Okechukwu, K.; Pierce, K.L.; Winner, J.D.; Zurhellen, W. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/ hyperactivity disorder in children and adolescents. Pediatrics, 2019, 144(4), e20192528. doi: 10.1542/peds.2019-2528 PMID: 31570648
  5. Kazda, L.; McGeechan, K.; Bell, K.; Thomas, R.; Barratt, A. Association of attention-deficit/hyperactivity disorder diagnosis with adolescent quality of life. JAMA Netw. Open, 2022, 5(10), e2236364. doi: 10.1001/jamanetworkopen.2022.36364 PMID: 36227598
  6. Katzman, M.A.; Bilkey, T.S.; Chokka, P.R.; Fallu, A.; Klassen, L.J. Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry, 2017, 17(1), 302. doi: 10.1186/s12888-017-1463-3 PMID: 28830387
  7. Gift, T.E.; Reimherr, F.W.; Marchant, B.K.; Steans, T.A.; Wender, P.H. Personality disorder in adult attention-deficit/hyperactivity disorder. J. Nerv. Ment. Dis., 2016, 204(5), 355-363. doi: 10.1097/NMD.0000000000000470 PMID: 27082828
  8. Salvi, V.; Ribuoli, E.; Servasi, M.; Orsolini, L.; Volpe, U. ADHD and bipolar disorder in adulthood: Clinical and treatment implications. Medicina, 2021, 57(5), 466. doi: 10.3390/medicina57050466 PMID: 34068605
  9. Ginsberg, Y.; Quintero, J.; Anand, E.; Casillas, M.; Upadhyaya, H.P. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: A review of the literature. Prim. Care Comp. CNS Disord., 2014, 16(3), PCC.13r01600. doi: 10.4088/PCC.13r01600 PMID: 25317367
  10. Coelho, R.M.; Drummond, C.; Mota, N.B.; Erthal, P.; Bernardes, G.; Lima, G.; Molina, R.; Sudo, F.K.; Tannock, R.; Mattos, P. Network analysis of narrative discourse and attention-deficit hyperactivity symptoms in adults. PLoS One, 2021, 16(4), e0245113. doi: 10.1371/journal.pone.0245113 PMID: 33826632
  11. Nelson, J.M.; Liebel, S.W. Anxiety and depression among college students with attention-deficit/hyperactivity disorder (ADHD): Cross-informant, sex, and subtype differences. J. Am. Coll. Health, 2018, 66(2), 123-132. doi: 10.1080/07448481.2017.1382499 PMID: 28937938
  12. Posner, J.; Polanczyk, G.V.; Sonuga-Barke, E. Attention-deficit hyperactivity disorder. Lancet, 2020, 395(10222), 450-462. doi: 10.1016/S0140-6736(19)33004-1 PMID: 31982036
  13. Young, J.L.; Goodman, D.W. Adult attention-deficit/hyperactivity disorder diagnosis, management, and treatment in the DSM-5 era. Prim. Care Companion CNS Disord., 2016, 18(6), 10.4088/PCC.16r02000. doi: 10.4088/PCC.16r02000 PMID: 27907271
  14. Turner, D.C.; Clark, L.; Dowson, J.; Robbins, T.W.; Sahakian, B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry, 2004, 55(10), 1031-1040. doi: 10.1016/j.biopsych.2004.02.008 PMID: 15121488
  15. Loland, C.J.; Mereu, M.; Okunola, O.M.; Cao, J.; Prisinzano, T.E.; Mazier, S.; Kopajtic, T.; Shi, L.; Katz, J.L.; Tanda, G.; Newman, A.H. R-modafinil (armodafinil): A unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol. Psychiatry, 2012, 72(5), 405-413. doi: 10.1016/j.biopsych.2012.03.022 PMID: 22537794
  16. Boellner, S.W.; Earl, C.Q.; Arora, S. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: A preliminary 8-week, open-label study. Curr. Med. Res. Opin., 2006, 22(12), 2457-2465. doi: 10.1185/030079906X148300 PMID: 17257460
  17. Swanson, J.M.; Greenhill, L.L.; Lopez, F.A.; Sedillo, A.; Earl, C.Q.; Jiang, J.G.; Biederman, J. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J. Clin. Psychiatry, 2006, 67(1), 137-147. doi: 10.4088/JCP.v67n0120 PMID: 16426100
  18. Gao, W-J.; Urban, K.R. Psychostimulants as cognitive enhancers in adolescents: More risk than reward? Front. Public Health, 2017, 5, 260. doi: 10.3389/fpubh.2017.00260 PMID: 29034227
  19. Minzenberg, M.J.; Carter, C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 2008, 33(7), 1477-1502. doi: 10.1038/sj.npp.1301534 PMID: 17712350
  20. Del-Ponte, B.; Anselmi, L.; Assunção, M.C.F.; Tovo-Rodrigues, L.; Munhoz, T.N.; Matijasevich, A.; Rohde, L.A.; Santos, I.S. Sugar consumption and attention-deficit/hyperactivity disorder (ADHD): A birth cohort study. J. Affect. Disord., 2019, 243, 290-296. doi: 10.1016/j.jad.2018.09.051 PMID: 30257225
  21. Kerekes, N.; Sanchéz-Pérez, A.M.; Landry, M. Neuroinflammation as a possible link between attention-deficit/hyperactivity disorder (ADHD) and pain. Med. Hypotheses, 2021, 157, 110717. doi: 10.1016/j.mehy.2021.110717 PMID: 34717072
  22. Sharma, A.; Couture, J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann. Pharmacother., 2014, 48(2), 209-225. doi: 10.1177/1060028013510699 PMID: 24259638
  23. Adler, L.A.; Faraone, S.V.; Spencer, T.J.; Berglund, P.; Alperin, S.; Kessler, R.C. The structure of adult ADHD. Int. J. Methods Psychiatr. Res., 2017, 26(1), e1555. doi: 10.1002/mpr.1555 PMID: 28211596
  24. Das, D.; Cherbuin, N.; Butterworth, P.; Anstey, K.J.; Easteal, S. A population-based study of attention deficit/hyperactivity disorder symptoms and associated impairment in middle-aged adults. PLoS One, 2012, 7(2), e31500. doi: 10.1371/journal.pone.0031500 PMID: 22347487
  25. Biederman, J.; Faraone, S.V.; Spencer, T.J.; Mick, E.; Monuteaux, M.C.; Aleardi, M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J. Clin. Psychiatry, 2006, 67(4), 524-540. doi: 10.4088/JCP.v67n0403 PMID: 16669717
  26. Fayyad, J.; De Graaf, R.; Kessler, R.; Alonso, J.; Angermeyer, M.; Demyttenaere, K.; De Girolamo, G.; Haro, J.M.; Karam, E.G.; Lara, C.; Lépine, J.P.; Ormel, J.; Posada-Villa, J.; Zaslavsky, A.M.; Jin, R. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br. J. Psychiatry, 2007, 190(5), 402-409. doi: 10.1192/bjp.bp.106.034389 PMID: 17470954
  27. Crunelle, C.L.; van den Brink, W.; Moggi, F.; Konstenius, M.; Franck, J.; Levin, F.R.; van de Glind, G.; Demetrovics, Z.; Coetzee, C.; Luderer, M.; Schellekens, A.; Matthys, F. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur. Addict. Res., 2018, 24(1), 43-51. doi: 10.1159/000487767 PMID: 29510390
  28. Castells, X.; Blanco-Silvente, L.; Cunill, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Libr., 2018, 2018(8), CD007813. doi: 10.1002/14651858.CD007813.pub3 PMID: 30091808
  29. Johnson, J.; Morris, S.; George, S. Attention deficit hyperactivity disorder in adults: What the non-specialist needs to know. Br. J. Hosp. Med., 2020, 81(3), 1-11. doi: 10.12968/hmed.2019.0188 PMID: 32240011
  30. Jaeschke, R.R.; Sujkowska, E.; Sowa-Kućma, M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: A narrative review. Psychopharmacology, 2021, 238(10), 2667-2691. doi: 10.1007/s00213-021-05946-0 PMID: 34436651
  31. Cortese, S.; Adamo, N.; Del Giovane, C.; Mohr-Jensen, C.; Hayes, A.J.; Carucci, S.; Atkinson, L.Z.; Tessari, L.; Banaschewski, T.; Coghill, D.; Hollis, C.; Simonoff, E.; Zuddas, A.; Barbui, C.; Purgato, M.; Steinhausen, H.C.; Shokraneh, F.; Xia, J.; Cipriani, A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 2018, 5(9), 727-738. doi: 10.1016/S2215-0366(18)30269-4 PMID: 30097390
  32. Greenhill, L.L.; Pliszka, S.; Dulcan, M.K.; Bernet, W.; Arnold, V.; Beitchman, J.; Benson, R.S.; Bukstein, O.; Kinlan, J.; McClellan, J.; Rue, D.; Shaw, J.A.; Stock, S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry, 2002, 41(2), 26S-49S. doi: 10.1097/00004583-200202001-00003 PMID: 11833633
  33. Pozzi, M.; Bertella, S.; Gatti, E.; Peeters, G.G.A.M.; Carnovale, C.; Zambrano, S.; Nobile, M. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin. Emerg. Drugs, 2020, 25(4), 395-407. doi: 10.1080/14728214.2020.1820481 PMID: 32938246
  34. Rugino, T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr. Dis. Treat., 2007, 3(3), 293-301. PMID: 19300563
  35. Biederman, J.; Faraone, S.V. Attention-deficit hyperactivity disorder. Lancet, 2005, 366(9481), 237-248. doi: 10.1016/S0140-6736(05)66915-2 PMID: 16023516
  36. Adler, L.A.; Liebowitz, M.; Kronenberger, W.; Qiao, M.; Rubin, R.; Hollandbeck, M.; Deldar, A.; Schuh, K.; Durell, T. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress. Anxiety, 2009, 26(3), 212-221. doi: 10.1002/da.20549 PMID: 19194995
  37. Walters, A.S.; Silvestri, R.; Zucconi, M.; Chandrashekariah, R.; Konofal, E. Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders. J. Clin. Sleep Med., 2008, 4(6), 591-600. doi: 10.5664/jcsm.27356 PMID: 19110891
  38. van Andel, E.; Bijlenga, D.; Vogel, S.W.N.; Beekman, A.T.F.; Kooij, J.J.S. Attention-deficit/hyperactivity disorder and delayed sleep phase syndrome in adults: A randomized clinical trial on the effects of chronotherapy on sleep. J. Biol. Rhythms, 2022, 37(6), 673-689. doi: 10.1177/07487304221124659 PMID: 36181304
  39. Gamble, K.L.; May, R.S.; Besing, R.C.; Tankersly, A.P.; Fargason, R.E. Delayed sleep timing and symptoms in adults with attention-deficit/hyperactivity disorder: A controlled actigraphy study. Chronobiol. Int., 2013, 30(4), 598-606. doi: 10.3109/07420528.2012.754454 PMID: 23445512
  40. Gau, S.S.F.; Kessler, R.C.; Tseng, W.L.; Wu, Y.Y.; Chiu, Y.N.; Yeh, C.B.; Hwu, H.G. Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep, 2007, 30(2), 195-201. doi: 10.1093/sleep/30.2.195 PMID: 17326545
  41. Mahajan, N.; Hong, N.; Wigal, T.L.; Gehricke, J.G. Hyperactive-impulsive symptoms associated with self-reported sleep quality in nonmedicated adults with ADHD. J. Atten. Disord., 2010, 14(2), 132-137. doi: 10.1177/1087054709347170 PMID: 19767595
  42. Kooij, J.J.S.; Bijlenga, D. The circadian rhythm in adult attention-deficit/hyperactivity disorder: current state of affairs. Expert Rev. Neurother., 2013, 13(10), 1107-1116. doi: 10.1586/14737175.2013.836301 PMID: 24117273
  43. Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharmacol., 2018, 175(16), 3190-3199. doi: 10.1111/bph.14116 PMID: 29318587
  44. Baird, A.L.; Coogan, A.N.; Siddiqui, A.; Donev, R.M.; Thome, J. Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol. Psychiatry, 2012, 17, 988-995. doi: 10.1038/mp.2011.149
  45. Coogan, A.N.; Baird, A.L.; Popa-Wagner, A.; Thome, J. Circadian rhythms and attention deficit hyperactivity disorder: The what, the when and the why. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 67, 74-81. doi: 10.1016/j.pnpbp.2016.01.006 PMID: 26776072
  46. Parekh, P.K.; Ozburn, A.R.; McClung, C.A. Circadian clock genes: Effects on dopamine, reward and addiction. Alcohol, 2015, 49(4), 341-349. doi: 10.1016/j.alcohol.2014.09.034 PMID: 25641765
  47. Hirshkowitz, M.; Black, J.E.; Wesnes, K.; Niebler, G.; Arora, S.; Roth, T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir. Med., 2007, 101(3), 616-627. doi: 10.1016/j.rmed.2006.06.007 PMID: 16908126
  48. Sousa, A.; Dinis-Oliveira, R.J. Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Subst. Abus., 2020, 41(2), 155-173. doi: 10.1080/08897077.2019.1700584 PMID: 31951804
  49. Schwartz, J.; Roth, T.; Drake, C. Armodafinil in the treatment of sleep/wake disorders. Neuropsychiatr. Dis. Treat., 2010, 6, 417-427. doi: 10.2147/NDT.S3004 PMID: 20856606
  50. Wang, S.M.; Han, C.; Lee, S.J.; Jun, T.Y.; Patkar, A.A.; Masand, P.S.; Pae, C.U. Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. J. Psychiatr. Res., 2017, 84, 292-300. doi: 10.1016/j.jpsychires.2016.09.034 PMID: 27810669
  51. Turner, D.C.; Robbins, T.W.; Clark, L.; Aron, A.R.; Dowson, J.; Sahakian, B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology, 2003, 165(3), 260-269. doi: 10.1007/s00213-002-1250-8 PMID: 12417966
  52. Taylor, F.B.; Russo, J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J. Child Adolesc. Psychopharmacol., 2000, 10(4), 311-320. doi: 10.1089/cap.2000.10.311 PMID: 11191692
  53. Amiri, S.; Mohammadi, M.R.; Mohammadi, M.; Nouroozinejad, G.H.; Kahbazi, M.; Akhondzadeh, S. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(1), 145-149. doi: 10.1016/j.pnpbp.2007.07.025 PMID: 17765380
  54. Rugino, T.A.; Copley, T.C. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(2), 230-235. doi: 10.1097/00004583-200102000-00018 PMID: 11211372
  55. Kaser, M.; Deakin, J.B.; Michael, A.; Zapata, C.; Bansal, R.; Ryan, D.; Cormack, F.; Rowe, J.B.; Sahakian, B.J. Modafinil improves episodic memory and working memory cognition in patients with remitted depression: A double-blind, randomized, placebo-controlled study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 2017, 2(2), 115-122. doi: 10.1016/j.bpsc.2016.11.009 PMID: 28299368
  56. Turner, D. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev. Neurother., 2006, 6(4), 455-468. doi: 10.1586/14737175.6.4.455 PMID: 16623645
  57. Coogan, A.N.; Schenk, M.; Palm, D.; Uzoni, A.; Grube, J.; Tsang, A.H.; Kolbe, I.; McGowan, N.M.; Wandschneider, R.; Colla, M.; Oster, H.; Thome, J.; Faltraco, F. Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology, 2019, 44(7), 1198-1206. doi: 10.1038/s41386-019-0327-6 PMID: 30758328
  58. Czeisler, C.A.; Walsh, J.K.; Wesnes, K.A.; Roth, T.; Arora, S. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: A randomized controlled study. Mayo Clin. Proc., 2009, 84(11), 958-972. doi: 10.1016/S0025-6196(11)60666-6 PMID: 19880686
  59. Schwartz, J.R.L.; Khan, A.; McCall, W.V.; Weintraub, J.; Tiller, J. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: A 12-month, open-label, flexible-dose study with an extension period. J. Clin. Sleep Med., 2010, 6(5), 450-457. doi: 10.5664/jcsm.27934 PMID: 20957845
  60. Gasior, M.; Freeman, J.; Zammit, G.; Donnelly, P.; Gao, J.; Ferreira-Cornwell, M.C.; Roth, T. Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss. J. Clin. Psychopharmacol., 2014, 34(6), 690-696. doi: 10.1097/JCP.0000000000000202 PMID: 25159886
  61. Dinges, D.F.; Arora, S.; Darwish, M.; Niebler, G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr. Med. Res. Opin., 2006, 22(1), 159-167. doi: 10.1185/030079906X80378 PMID: 16393442
  62. Rosenberg, R.P.; Bogan, R.K.; Tiller, J.M.; Yang, R.; Youakim, J.M.; Earl, C.Q.; Roth, T. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin. Proc., 2010, 85(7), 630-638. doi: 10.4065/mcp.2009.0778 PMID: 20530317
  63. Harsh, J.R.; Hayduk, R.; Rosenberg, R.; Wesnes, K.A.; Walsh, J.K.; Arora, S.; Niebler, G.E.; Roth, T. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr. Med. Res. Opin., 2006, 22(4), 761-774. doi: 10.1185/030079906X100050 PMID: 16684437
  64. Roth, T.; Rippon, G.A.; Arora, S. Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath., 2008, 12(1), 53-62. doi: 10.1007/s11325-007-0137-7 PMID: 17874255
  65. Page, B.R.; Shaw, E.G.; Lu, L.; Bryant, D.; Grisell, D.; Lesser, G.J.; Monitto, D.C.; Naughton, M.J.; Rapp, S.R.; Savona, S.R.; Shah, S.; Case, D.; Chan, M.D. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro-oncol., 2015, 17(10), 1393-1401. doi: 10.1093/neuonc/nov084 PMID: 25972454
  66. Bruce, J.; Hancock, L.; Roberg, B.; Brown, A.; Henkelman, E.; Lynch, S. Impact of armodafinil on cognition in multiple sclerosis: A randomized, double-blind crossover pilot study. Cogn. Behav. Neurol., 2012, 25(3), 107-114. doi: 10.1097/WNN.0b013e31826df7fd PMID: 22960434
  67. Frye, M.A.; Ketter, T.A.; Yang, R.; Calabrese, J.R. A double-blind, placebo-controlled, multicenter trial of adjunctive armodafinil for the treatment of major depression associated with bipolar I disorder. Value Health, 2013, 16(3), A55-A56. doi: 10.1016/j.jval.2013.03.1552
  68. Greve, D.N.; Duntley, S.P.; Larson-Prior, L.; Krystal, A.D.; Diaz, M.T.; Drummond, S.P.A.; Thein, S.G.; Kushida, C.A.; Yang, R.; Thomas, R.J. Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: A multicenter fMRI study. J. Clin. Sleep Med., 2014, 10(2), 143-153. doi: 10.5664/jcsm.3440 PMID: 24532997
  69. Repantis, D.; Bovy, L.; Ohla, K.; Kühn, S.; Dresler, M. Cognitive enhancement effects of stimulants: A randomized controlled trial testing methylphenidate, modafinil, and caffeine. Psychopharmacology, 2021, 238(2), 441-451. doi: 10.1007/s00213-020-05691-w PMID: 33201262
  70. Kis, B.; Lücke, C.; van Elst, L.T.; Müller, H.H.O.; Philipsen, A.; Abdel-Hamid, M.; Heßmann, P.; Graf, E.; Berger, M.; Matthies, S.; Borel, P.; Sobanski, E.; Alm, B.; Rösler, M.; Retz, W.; Jacob, C.; Colla, M.; Huss, M.; Jans, T. Safety profile of methylphenidate under long-term treatment in adult ADHD patients - results of the COMPAS study. Pharmacopsychiatry, 2020, 53(6), 263-271. doi: 10.1055/a-1207-9851 PMID: 33017854
  71. Weisler, R.; Young, J.; Mattingly, G.; Gao, J.; Squires, L.; Adler, L. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr., 2009, 14(10), 573-586. doi: 10.1017/S1092852900024056 PMID: 20095369
  72. Findling, R.L.; Cutler, A.J.; Saylor, K.; Gasior, M.; Hamdani, M.; Ferreira-Cornwell, M.C.; Childress, A.C. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol., 2013, 23(1), 11-21. doi: 10.1089/cap.2011.0088 PMID: 23410138
  73. Bobo, W.V.; Woodward, N.D.; Sim, M.Y.; Jayathilake, K.; Meltzer, H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial. Schizophr. Res., 2011, 130(1-3), 106-113. doi: 10.1016/j.schres.2011.05.015 PMID: 21641776
  74. Lapid, M.I.; Kuntz, K.M.; Mason, S.S.; Aakre, J.A.; Lundt, E.S.; Kremers, W.; Allen, L.A.; Drubach, D.A.; Boeve, B.F. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with lewy bodies: A pilot study. Dement. Geriatr. Cogn. Disord., 2017, 43(5-6), 269-280. doi: 10.1159/000471507 PMID: 28448998
  75. Menn, S.J.; Yang, R.; Lankford, A. Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: A 12-week, randomized, double-blind study followed by a 12-month open-label extension. J. Clin. Sleep Med., 2014, 10(11), 1181-1191. doi: 10.5664/jcsm.4196 PMID: 25325609
  76. Kuan, Y-C.; Wu, D.; Huang, K-W.; Chi, N-F.; Hu, C-J.; Chung, C-C.; Tam, K-W.; Huang, Y-H. Effects of modafinil and armodafinil in patients with obstructive sleep apnea: A meta-analysis of randomized controlled trials. Clin. Ther., 2016, 38(4), 874-888. doi: 10.1016/j.clinthera.2016.02.004 PMID: 26923035
  77. Wisor, J.; Dement, W.; Aimone, L.; Williams, M.; Bozyczkocoyne, D. Armodafinil, the R-enantiomer of modafinil: Wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol. Biochem. Behav., 2006, 85(3), 492-499. doi: 10.1016/j.pbb.2006.09.018 PMID: 17134745
  78. Kreutzmann, J.C.; Havekes, R.; Abel, T.; Meerlo, P. Sleep deprivation and hippocampal vulnerability: Changes in neuronal plasticity, neurogenesis and cognitive function. Neuroscience, 2015, 309, 173-190. doi: 10.1016/j.neuroscience.2015.04.053 PMID: 25937398
  79. Zhu, S.; Zhang, S.; Pang, L.; Ou, G.; Zhu, L.; Ma, J.; Li, R.; Liu, Y.; Wang, L.; Wang, L.; Du, L.; Jin, Y. Effects of armodafinil nanocrystal nasal hydrogel on recovery of cognitive function in sleep-deprived rats. Int. J. Pharm., 2021, 597, 120343. doi: 10.1016/j.ijpharm.2021.120343 PMID: 33545288
  80. Fiocchi, E.M.; Lin, Y.G.; Aimone, L.; Gruner, J.A.; Flood, D.G. Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacol. Biochem. Behav., 2009, 92(3), 549-557. doi: 10.1016/j.pbb.2009.02.006 PMID: 19249327
  81. Lu, J.; Greco, M.A.; Shiromani, P.; Saper, C.B. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J. Neurosci., 2000, 20(10), 3830-3842. doi: 10.1523/JNEUROSCI.20-10-03830.2000 PMID: 10804223
  82. Fuller, P.; Vetrivelan, R.; Saper, C. Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions. Nat. Sci. Sleep, 2014, 6, 57-63. doi: 10.2147/NSS.S53132 PMID: 24833927
  83. Concetta Scuto, M.; Mancuso, C.; Tomasello, B.; Laura, O.M.; Cavallaro, A.; Frasca, F.; Maiolino, L.; Trovato, S.A.; Calabrese, E.J.; Calabrese, V. Curcumin, hormesis and the nervous system. Nutrients, 2019, 11(10), 2417. doi: 10.3390/nu11102417 PMID: 31658697
  84. Calabrese, V.; Cornelius, C.; Dinkova-Kostova, A.T.; Calabrese, E.J.; Mattson, M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: Novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal., 2010, 13(11), 1763-1811. doi: 10.1089/ars.2009.3074
  85. Calabrese, V.; Giordano, J.; Signorile, A.; Laura Ontario, M.; Castorina, S.; De Pasquale, C.; Eckert, G.; Calabrese, E.J. Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. J. Neurosci. Res., 2016, 94(12), 1588-1603. doi: 10.1002/jnr.23925 PMID: 27662637
  86. Sai, K.S.; Akkiraju, S.; Chinni, S.; Kanala, S.R. Evaluation of armodafinil’s anti-amnestic activity in scopolamine-induced amnesia in wistar rats. J. Young Pharm., 2023, 15(1), 83-91. doi: 10.5530/097515050389

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers